Testing CBD oil for seizures in developmental and epileptic encephalopathy
Part of Brain & nervous system clinical trials.
This study tests a new CBD oil (CBD-OS) to see if it safely reduces seizures in people with developmental and epileptic encephalopathy (DEE), a condition where both development and seizure control are affected. Participants must already be on a stable antiseizure treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 1 year old.
- You have been diagnosed with developmental and epileptic encephalopathy (DEE), meaning your development and seizures are both affected.
- You are currently on a stable dose of at least one epilepsy medication, a ketogenic diet, or a nerve stimulation device.
- Your epilepsy treatments have not changed in the last 28 days and won't change during the main study period.
- You have had genetic or imaging tests to find the cause of your DEE, or you are willing to have them.
- You have not tried or failed a proper course of Epidiolex (a different CBD medicine) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This trial tests if cannabinoids can help people who still have seizures despite trying two or more standard seizure medications. It aims to reduce seizure frequency in those with drug-resistant epilepsy.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
Hear when a new Developmental and Epileptic Encephalopathy (DEE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.